|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
|
Neos Therapeutics, Inc. (NEOS) |
|
|
$1.15 0.00 (0.00%) as of 4:30 Fri 3/19
|
|
Download |
|
| |
Company
Roster
|
|
Total
Insiders : |
21 |
|
|
|
Total
Direct Shares :
|
2,948,661 |
|
|
Total
Indirect Shares :
|
5,896,464 |
| |
%
Held by Insiders:
|
5.93% |
|
|
| |
| Filer's Name |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
  Fong Bryant |
Director |
2021-03-19 |
0 |
2016-08-31 |
0 |
| Heller Alan L |
Director |
2021-03-19 |
0 |
|
0 |
| Limongelli John M |
SVP & General Counsel |
2021-03-19 |
0 |
2020-03-02 |
0 |
| Eisenstadt Richard I |
Chief Financial Officer |
2021-03-19 |
0 |
2016-08-25 |
0 |
| Schmid John P. |
Director |
2021-03-19 |
0 |
2020-06-10 |
0 |
| Szyper Linda M |
Director |
2021-03-19 |
0 |
|
0 |
| Hecht Beth |
Director |
2021-03-19 |
0 |
2020-06-10 |
0 |
| Robitaille Gregory J |
Director |
2021-03-19 |
0 |
|
0 |
| Mclaughlin Gerald W. |
Chief Executive Officer, Director |
2021-03-19 |
0 |
2018-12-04 |
0 |
| Robinson James A. Jr. |
Director |
2021-03-19 |
0 |
2020-06-10 |
0 |
| Mcdonnell Thomas P |
Chief Commercial Officer |
2018-05-01 |
35,864 |
2016-05-19 |
0 |
| Engelking Dorothy |
VP, Regulatory Affairs |
2018-03-01 |
10,416 |
2015-07-28 |
0 |
| Garg Vipin K |
Chief Executive Officer |
2018-03-01 |
160,748 |
|
0 |
| Martens Juergen |
Chief Tech/Operations Officer |
2017-05-01 |
25,000 |
2016-06-13 |
0 |
| Sohail Faysal A. |
10% Owner |
2016-04-20 |
1,559,995 |
2016-04-20 |
39,998 |
| Schuler Jack W |
10% Owner |
2015-07-28 |
1,044,578 |
2017-02-17 |
2,338,671 |
| Deerfield Private Design Fund Iii, L.p. |
Possible Member of 10% Group, 10% Owner |
2015-07-28 |
0 |
2015-07-28 |
429,166 |
| Delaware Street Capital L P |
10% Owner |
2015-07-28 |
0 |
2015-07-28 |
907,358 |
| Tengler Mark |
Chief Technology Officer |
2015-07-28 |
112,060 |
|
0 |
| Dalal Anupam |
10% Owner |
2015-07-28 |
0 |
2015-07-28 |
1,215,052 |
| Essex Capital Corp |
10% Owner |
|
0 |
2015-07-28 |
966,219 |
|
|
